Gastric mucin expression in Helicobacter pylori-related, nonsteroidal anti-inflammatory drug-related and idiopathic ulcers

doi:10.3748/wjg.v18.i33.4597

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 33

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3956)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

373

HTML

3129

Figures (1-1)

239

Tables (1-6)

215

Sum=3956

Sep 7, 2012 (publication date) through Nov 20, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Sep 7, 2012; 18(33): 4597-4603
Published online Sep 7, 2012. doi: 10.3748/wjg.v18.i33.4597

Table 1 Patient characteristics

	H. pylori+/NSAID-	H. pylori-/NSAID+	H. pylori+/NSAID+	H. pylori-/NSAID-	Total
	n = 30 (32.6%)	n = 18 (19.6%)	n = 24 (26.1%)	n = 20 (21.7%)	n = 92
Age, yr [mean (SD, range)]	58.6 (18.58, 18-88)	72.17 (10.44, 56-89)	69.46 (13.08, 24-83)	70.3 (12.64, 42-95)	66.6 (15.5, 18-95)
Gender (male) n (%)	10 (33)	9 (50)	13 (54.2)	12 (60)	44 (47.8)
Ethnicity n (%)
Israeli (Jewish)	11 (36.7)	9 (50)	12 (50)	6 (30)	38 (41.3)
Israeli (Arab)	3 (10)	0 (0)	2 (8.3)	1 (5)	6 (6.5)
Western Europe/United States	7 (23.3)	0 (0)	1 (4.2)	2 (10)	10 (10.9)
Eastern Europe/FSU	2 (6.7)	6 (33.3)	6 (25)	6 (30)	20 (21.7)
Middle east/Africa	7 (23.3)	2 (11.1)	3 (12.5)	4 (20)	16 (17.4)
South America	0 (0)	1 (5.6)	0 (0)	1 (5)	2 (2.2)
Inpatient n (%)	11 (36.7)	12 (60)	10 (41.7)	16 (80)	49 (53.3)
Comorbid disease n (%)
ASCVD	3 (10)	12 (66.7)	11 (45.8)	6 (30)	32 (34.8)
COPD	2 (6.7)	4 (22.2)	2 (8.3)	7 (35)	15 (16.3)
Diabetes	4 (13.3)	4 (22.2)	12 (50)	6 (30)	26 (28.3)
Current malignancy	1 (3.3)	2 (11.1)	2 (8.3)	2 (10)	7 (7.6)
Alcohol abuse	0 (0)	0 (0)	0 (0)	3 (15)	3 (3.3)
Other significant systemic disease	1 (3.3)³	1 (5.6)⁴	1 (4.2)⁴	5 (25)⁵	8 (8.7)
Total¹	7 (23.3)	15 (83.3)	19 (79.2)	14 (70)	55 (59.8)
Primary indication for endoscopy n (%)
Iron deficiency anemia	9 (30)	5 (27.8)	6 (25)	1 (5)	21 (22.8)
Epigastric pain/GERD	8 (26.7)	6 (33.3)	4 (16.5)	4 (20)	22 (23.9)
Upper GI bleeding	7 (23.3)	6 (33.3)	6 (25)	9 (45)	28 (30.4)
Fecal occult blood	2 (6.7)	0 (0)	1 (4.2)	1 (5)	4 (4.3)
Weight loss	2 (6.7)	1 (5.6)	5 (20.8)	0 (0)	8 (8.7)
Screening for gastric cancer	2 (6.7)	0 (0)	0 (0)	0 (0)	2 (2.2)
Esophageal varices	0 (0)	0 (0)	0 (0)	2 (10)	2 (2.2)
Vomiting	0 (0)	0 (0)	0 (0)	1 (5)	1 (1.1)
Other²	0 (0)	0 (0)	2 (8.3)	2 (10)	4 (4.3)
Hemoglobin, g/dL [mean (SD, range)]	11.0 (3.22, 3.4-16.7)	10.6 (2.77, 5.5-15.5)	11.0 (2.84, 5.7-14.7)	11.1 (2.70, 6.2-15.3)	10.9 (2.98, 3.4-16.7)
Died within 12 mo of endoscopy	3 (10)	2 (11.1)	2 (8.3)	5 (25)	12 (13.0)

¹Number of patients with comorbidities as listed;

²Fever unknown origin, gastric outlet obstruction, and surveillance following resection of gastric and esophageal carcinoma (1 case for each indication);

³Inflammatory bowel disease;

⁴Hemodialysis;

⁵Inflammatory bowel disease, sepsis, cirrhosis (2 cases), tetraplegia following trauma. H. pylori: Helicobacter pylori; NSAID: Non-steroidal anti-inflammatory drugs; ASCVD: Atherosclerotic cardiovascular disease; COPD: Chronic obstructive pulmonary disease; GERD: Gastro esophageal reflux disease; GI: Gastrointestinal. +: Positive; -: Negative.

Table 2 Endoscopic findings

	H. pylori+/NSAID-	H. pylori-/NSAID+	H. pylori+/NSAID+	H. pylori-/NSAID-	Total
	n = 30 (32.6%)	n = 18 (19.6%)	n = 24 (26.1%)	n = 20 (21.7%)	n = 92
Ulcer number (per procedure) n (%)
1	21 (70)	10 (55.6)	13 (54.2)	14 (70)	58 (63.0)
2	4 (13.3)	3 (16.7)	5 (20.8)	3 (15)	15 (16.3)
≥ 3	5 (16.7)	5 (27.8)	6 (25)	3 (15)	19 (20.7)
Ulcer size (n)¹
≤ 5 mm	18	14	27	14	73
6-10 mm	7	8	10	11	36
11-20 mm	5	3	4	4	16
> 20 mm	4	0	0	2	6
Not specified	2	2	2	0	6
Ulcer location n (%)
Antrum	19 (63.3)	10 (55.6)	18 (75)	16 (80)	63 (68.5)
Body	9 (30)	6 (33.3)	6 (25)	4 (20)	25 (27.2)
Cardia	2 (6.7)	2 (11.1)	0 (0)	0	4 (4.3)
Ulcer H. pylori positive n (%)	28 (93.3)²	0 (0)	20 (83.3)	0 (0)	48 (52.2)
Ulcer IM n (%)	5 (16.7)	4 (22.2)	3 (16.7)	4 (20)	16 (17.4)

¹In 10 instances the endoscopist reported “ulcer number” as “multiple”. Therefore the total number of ulcers is unknown and percentages cannot be calculated;

²Cases where H. pylori was absent from ulcer margin, but had either positive rapid urease test, positive C13-urea breath test or positive histology in biopsy not taken from ulcer margin. NSAID: Non-steroidal anti-inflammatory drugs; H. pylori: Helicobacter pylori; IM: Intestinal metaplasia. +: Positive; -: Negative.

Table 3 Staining positivity for mucin 5AC and mucin 6 n (%)

		Mucin 5AC			Mucin 6
		Surface cell positivity	Neck cell positivity	Gland cell positivity	Surface cell positivity	Neck cell positivity	Gland cell positivity
H. pylori+/NSAID-	a	29 (96.7)	29 (96.7)	2 (6.7)	0 (0)	4 (13.3)	29 (96.7)
(n = 30)	b	29 (96.6)	27 (90)	0 (0)	0 (0)	1 (3.3)	25 (83.3)
H. pylori-/NSAID+	a	18 (100)	18 (100)	2 (11.1)	0 (0)	4 (22.2)	17 (94.4)
(n = 18)	b	16 (88.9)	15 (83.3)	0 (0)	0 (0)	2 (11.1)	14 (77.8)
H. pylori+/NSAID+	a	24 (100)	24 (100)	2 (8.3)	0 (0)	5 (20.8)	24 (100)
(n = 24)	b	24 (100)	23 (95.8)	2 (8.3)	0 (0)	2 (8.3)	22 (91.7)
H. pylori-/NSAID-	a	20 (100)	20 (100)	0 (0)	0 (0)	5 (25)	20 (100)
(n = 20)	b	19 (95)	16 (80)	0 (0)	0 (0)	1 (5)	19 (95)
Total	a	91 (98.9)	91 (98.9)	6 (6.5)	0 (0)	18 (19.6)	90 (97.8)
(n = 92)	b	88 (95.7)	81 (88.0)	2 (2.2)	0 (0)	6 (6.5)	80 (97.0)

a: Positive stain defined as a stain extent and intensity score product ≥ 2; b: Strongly positive stain, defined as a stain extent and intensity score product equalling 6 or 9. H. pylori: Helicobacter pylori; NSAID: Non-steroidal anti-inflammatory drugs. +: Positive; -: Negative.

Table 4 Effect of Helicobacter pylori and non-steroidal anti-inflammatory drug status on mucin staining

	H. pylori+	H. pylori-	P value	NSAID+	NSAID-	P value
MUC5AC
Surface cell positivity	53/54 (98.1)	38/38 (100)	0.39	42/42 (100)	49/50 (98)	0.36
Neck cell positivity	53/54 (98.1)	38/38 (100)	0.39	42/42 (100)	49/50 (98)	0.36
Gland cell positivity	4/54 (7.4)	2/38 (5.3)	0.68	4/42 (9.5)	2/50 (4)	0.29
MUC6
Surface cell positivity	0/54 (0)	0/38 (0)	NA	0/42 (0)	0/50 (0)	NA
Neck cell positivity	9/54 (16.7)	9/38 (23.7)	0.40	9/42 (21.4)	9/50 (18)	0.68
Gland cell positivity	53/54 (98.1)	37/38 (97.4)	0.80	41/42 (97.6)	49/50 (98)	0.90

H. pylori: Helicobacter pylori; NSAID: Non-steroidal anti-inflammatory drugs; NA: Not available. +: Positive; -: Negative.

Table 5 Intraepithelial/mucosal T-cell populations (n = 20)

Group	CD4+/CD8+	CD8+/HPF	CD4+/HPF
H. pylori+/NSAID-	3.15	22.0 ± 4.4	69.6 ± 38.2^a
H. pylori-/NSAID+	0.55	14.0 ± 9.4	8.4 ± 12.5
H. pylori+/NSAID+	2.99	26.6 ± 20.9	50.0 ± 25.2
H. pylori-/NSAID-	1.15	29.0 ± 11.4	38.0 ± 27.7

^aP = 0.009 vs H. pylori-/NSAID+ group. H. pylori: Helicobacter pylori; NSAID: Non-steroidal anti-inflammatory drugs; HPF: High-power field.

Table 6 Inflammation score according to the Sydney system (n = 20)

Group	H. pylori	Atrophy	Intestinal metaplasia	Lymphocytes	PMN	Score
H. pylori+/NSAID-	2.20 ± 0.44	0.60 ± 0.54	0.40 ± 0.54	1.80 ± 0.83	1.20 ± 1.30	6.20 ± 2.48^a
H. pylori-/NSAID+	0.00 ± 0.00	0.40 ± 0.54	0.60 ± 1.34	1.40 ± 0.89	0.20 ± 0.44	2.60 ± 2.19
H. pylori+/NSAID+	1.80 ± 1.09	0.80 ± 0.83	0.40 ± 0.89	2.00 ± 0.70	1.40 ± 0.89	6.40 ± 3.13
H. pylori-/NSAID-	0.00 ± 0.00	0.20 ± 0.44	0.20 ± 0.44	1.40 ± 0.54	0.40 ± 0.54	2.20 ± 1.64

^aP = 0.017 vs H. pylori-/NSAID- group. PMN: Polymorphonuclear cells; H. pylori: Helicobacter pylori; NSAID: Non-steroidal anti-inflammatory drugs.

Citation: Boltin D, Halpern M, Levi Z, Vilkin A, Morgenstern S, Ho SB, Niv Y. Gastric mucin expression in Helicobacter pylori-related, nonsteroidal anti-inflammatory drug-related and idiopathic ulcers. World J Gastroenterol 2012; 18(33): 4597-4603
URL: https://www.wjgnet.com/1007-9327/full/v18/i33/4597.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i33.4597